Login to Your Account



AZ brings its biologic pipeline to China; inks exclusive Wuxi deal

By Shannon Ellis
Staff Writer

Thursday, December 17, 2015

SHANGHAI – Astrazeneca plc, of London, is betting that a "made-in-China" label will shave years off the usual CFDA review and approval timelines that imported drugs face.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription